Reglutide 0.5 PFS

GLP-1 receptor agonist (weekly injection or daily tablet) for:

• Type 2 diabetes in adults (with diet and exercise); reduces cardiovascular events in people with heart disease
• Chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with weight-related conditions (higher-dose injection)

Weekly injection (diabetes): 0.25 mg once weekly for 4 weeks, then 0.5 mg weekly; after at least 4 weeks may increase to 1 mg, then 2 mg weekly if needed.

Weekly injection (weight management): 0.25 mg → 0.5 → 1 → 1.7 → 2.4 mg weekly, increasing every 4 weeks.

Tablet (diabetes): 3 mg once daily for 30 days, then 7 mg; may increase to 14 mg daily. Take on an empty stomach with no more than 120 ml water, at least 30 minutes before food, drink or other medicines; swallow whole.

• Injection: same day each week, abdomen/thigh/upper arm; missed dose within 5 days can be taken.
• Reduce insulin or sulphonylurea doses as advised.

• Personal or family history of medullary thyroid carcinoma or MEN2
• Allergy to semaglutide
• Type 1 diabetes, diabetic ketoacidosis

Very common: nausea, vomiting, diarrhoea, constipation, abdominal pain, reduced appetite (mostly when increasing dose).

Common: indigestion, burping, bloating, tiredness, dizziness, low blood sugar (with insulin/sulphonylureas), gallstones, headache, hair loss.

Rare but serious: pancreatitis, gallbladder inflammation, kidney injury from dehydration, worsening diabetic retinopathy (rapid sugar improvement), severe allergic reactions, aspiration risk during anaesthesia, possible thyroid tumours (animal studies).

• Stop and seek help for severe persistent abdominal pain.
• Drink enough fluids during stomach upset.
• Diabetic retinopathy: eye monitoring.
• Tell the anaesthetist before procedures.
• Report neck lump, hoarseness or difficulty swallowing.

Do not use in pregnancy; stop at least 2 months before a planned pregnancy. Not recommended while breastfeeding.

• Insulin, sulphonylureas (hypoglycaemia)
• Oral medicines with narrow safety margin (warfarin, levothyroxine) — monitor; oral semaglutide raises levothyroxine exposure
• Do not combine with other GLP-1 agonists

Severe nausea and vomiting, low blood sugar. Supportive care; long-acting — prolonged observation.

Injection pens: refrigerate (2–8°C) before first use; do not freeze; after first use may be kept below 30°C for up to 6 weeks (as per pack). Tablets: below 30°C in the original blister.